Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of aripiprazole orally disintegrating tablets on oral health and oral microbiome in schizophrenia
ChiCTR2200056872Phase 4Recruiting
- Sponsor
- Huizhou Second People's Hospital
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of aripiprazole in schizophrenia (2 arms), sponsored by Huizhou Second People's Hospital. Primary endpoints: Oral health scale and Oral microbiome. Started Nov 2021; status: recruiting.
02
Drugs
aripiprazole
03
Conditions
schizophrenia
Beyond the preview
Go deeper on ChiCTR2200056872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056872.